Skip to main content
CRNX
NASDAQ Life Sciences

Crinetics Pharmaceuticals Reports Strong Q1 Product Revenue Growth and Robust Liquidity Post-$380M Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$43.042
Mkt Cap
$4.554B
52W Low
$25.83
52W High
$57.99
52W Position info
67% above low
Off High info
26% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

CRNX sits 67% above its 52-week low of $25.83 on elevated volume (1.8× avg).

Summary

Crinetics Pharmaceuticals reported strong Q1 product revenue growth for PALSONIFY and a robust cash position following a $380 million public offering, alongside continued pipeline and global regulatory progress.


Key Events · Earnings and Guidance · CRNX

  • Strong Product Revenue Growth

    Q1 2026 product revenue reached $10.3 million, a significant increase from $5.4 million in Q4 2025, driven by the successful commercial launch of PALSONIFY.

  • Robust Liquidity and Capital Raise

    The company ended Q1 2026 with $1.3 billion in cash, cash equivalents, and investment securities, following a $380 million underwritten public offering completed in January 2026. This provides sufficient capital for at least the next 12 months.

  • Positive PALSONIFY Commercial Uptake

    Reported 232 Enrollment Forms and 263 unique healthcare providers prescribing PALSONIFY in Q1 2026, with approximately 70% of patients on reimbursed therapy.

  • Global Regulatory Progress for PALSONIFY

    Received European Commission approval in April 2026 (previously announced), submitted a Marketing Authorization Application in Brazil, and achieved a $1.5 million milestone payment from SKK for an NDA submission in Japan.


Analysis · CRNX · Life Sciences

Crinetics Pharmaceuticals delivered a strong first-quarter report, showcasing significant product revenue growth and a robust financial position. The company's lead product, PALSONIFY, demonstrated strong commercial uptake with a near 90% sequential increase in product revenue. A substantial $380 million public offering completed in January 2026 has significantly bolstered the company's cash reserves, providing a long runway for operations and pipeline development. Continued global regulatory progress for PALSONIFY further de-risks its commercialization strategy. While net losses increased due to investments in commercialization and R&D, the overall financial health and operational momentum are positive for the company's growth trajectory. The adoption of a 10b5-1 plan by the CSO is a routine, pre-planned sale and a minor event in the context of these broader positive developments.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRNX was trading at $43.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $25.83 to $57.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRNX - Latest Insights

CRNX
Sep 01, 2026, 9:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $84.97
Real-time Price: $84.97 info
Change: $0 (0%) info
Market Cap: $9.01B info
CRNX
Aug 28, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $84.84
Real-time Price: $84.97 info
Change: +$0.130 (+0.15%) info
Market Cap: $9.01B info
CRNX
Aug 19, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $84.70
Real-time Price: $84.97 info
Change: +$0.270 (+0.32%) info
Market Cap: $9.01B info
CRNX
Aug 14, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $84.41
Real-time Price: $84.97 info
Change: +$0.560 (+0.66%) info
Market Cap: $9.01B info
CRNX
Aug 03, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $83.76
Real-time Price: $84.97 info
Change: +$1.21 (+1%) info
Market Cap: $9.01B info